Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
OKOKYO Pharma Limited logo

OKYO Pharma Limited (OKYO)

NASDAQ Capital Market · Currency in USD
$1.40 ▼ -0.07 (-4.76%)
At close: Oct 23, 4:00 PM ET. Market closed.
$1.40 ▲ +0.00 (+0.00%)
After hours: Oct 23, 4:10 PM ET

Summary

Previous Close
$1.47
Open
$1.42
Day's Range
$1.40 – $1.43
52 Week Range
$1.26 – $3.20
Volume
13,848
Avg. Volume
92,626
Market Cap
$73.47M
Beta (5Y Monthly)
0.05
PE Ratio (TTM)
--
EPS (TTM)
-$0.24
Earnings Date
Dec 2, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$5.00

Profile: OKYO Pharma Limited

Sector
Healthcare
Industry
Biotechnology
Full-time employees
5
CEO
Robert J. Dempsey

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain.

Earnings

Next report: Wed, Dec 2, 2026
EPS estimate -$0.06
DateEst.Actual
Jul 20, 2026-$0.08-$0.15Miss
Jan 30, 2026-$0.07-$0.01Beat
Jul 18, 2025-$0.05-$0.04Beat
Jan 29, 2025–-$0.08
Oct 2, 2024–-$0.08
May 13, 2024–-$0.30

Analyst view

Consensus price target
$5.00 ▲ +257.1%
Range $5.00 – $5.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on OKYO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.